Summary: Pruli‰oxacin (PUFX) is a prodrug-type new quinolone antibiotic and immediately converted to an active metabolite, uli‰oxacin (UFX). It has been previously reported that UFX is highly excreted into the bile, although the hepatic uptake process of UFX has not been investigated yet. In this study, we attempted to characterize the mechanism of hepatic uptake of UFX in rats. The hepatic uptake in vivo was evaluated by integration plot analysis. Furthermore, the uptake of [
Introduction
Pruli‰oxacin (PUFX) is a prodrug-type new quinolone antibiotic. After absorption, PUFX is quickly converted to an active metabolite, uli‰oxacin (UFX; Fig.  1 ). UFX is a zwitter ionic compound. UFX has strong antimicrobial activities against gram-positive and -negative bacteria and shows reasonable e‹cacy in infections in the various tissues, including a bile duct. In humans, although urinary excretion is a major elimination route of UFX, 1) UFX is highly excreted into the bile. 2) Such high concentration in the bile could be one of the reasons why UFX is eŠective against bile duct infections. Therefore, it would be desirable to clarify the mechanism(s) underlying the biliary excretion process to understand pharmacological e‹cacy of PUFX.
The hepatobiliary transport of drugs is a complex process including hepatic uptake and excretion into the bile. The study on the excretion process of UFX into the bile has been reported. 3) UFX was e‹ciently excreted into the bile in rats, with its concentration in the bile being 30-60 times higher than that in the plasma.
3) It was shown that UFX was a substrate of P-glycoprotein. Nevertheless, the biliary clearance of UFX in Pglycoprotein-gene-deˆcient mice was not diŠerent from that in the normal mice.
3) Thus, involvement of Pglycoprotein in the UFX excretion would be minor, and multiple transport systems are involved in the transport on canalicular membranes.
On the other hand, the hepatic uptake process of UFX has not been investigated yet. A number of transporters responsible for sinusoidal hepatic uptake have been cloned and their transport properties have been determined in rats and humans. 4, 5) In rats, these include organic anion transporting polypeptides (Oatps), organic anion transporters (OATs), organic cation transporters (OCTs) and Na ＋ -taurocholate co-transporting polypeptides (Ntcp). It has been reported that many drugs and endogenous compounds are taken up into hepatocytes via these transporters. [6] [7] [8] Uptake mechanism for some quinolone antibiotics have been also investigated: HSR-903 and Grepa‰oxacin (GPFX) are reported to be taken up into hepatocytes via carrier-mediated active transporters, but these are distinct from those involved in the transport of bile acids, organic anions, organic cations or neutral steroids. [9] [10] [11] In addition, it has been indicated that there is a diŠerence in the transport mechanism among quinolone antibiotics. 10, 11) Thus, the hepatic uptake mechanism of quinolone antibiotics has not beenˆnally identiˆed.
The purpose of this study was to characterize the mechanism of hepatic uptake of UFX with an aim to elucidate the beneˆcial pharmacokinetic behavior of PUFX.
Materials and Methods
Chemicals: UFX ((±)-6-‰uoro-1-methyl-4-oxo-7-(1-piperazinyl)-4H- [1, 3] Cell preparation: Hepatocytes were isolated from rats by procedure of a previous report. 12) After isolation, the hepatocytes were suspended (1.25×10 6 cells/mL) at 49 C in albumin-free Krebs-Henseleit buŠer with 5 mM Glucose (pH 7.4). We checked cell viability by a trypan blue exclusion test and used the hepatocytes showing more than 90z viability. Cellular protein content was determined according to the method of Bradford protein assay using bovine serum albumin as standard.
13)
Determination of UFX concentration: The concentrations of UFX in the plasma and liver were determined by HPLC method after solid-phase extraction of the samples. Brie‰y, a plasma sample (0.1 mL) was added with the internal standard (I.S., 0.1 mL, 2.5 mg/mL ENX), distilled water (0.1 mL) and 10 mM phosphate buŠer (2.7 mL, pH 6.0). A liver sample was homogenized with four times of its volume of saline. Twenty z homogenates of the liver (0.1 mL) was added with the internal standard (0.5 mg/mL ENX, 0.1 mL) and centrifuged at 10000 rpm for 5 min. The supernatant was added with ehyl chlorocarbonate (0.02 mL), and added with distilled water (2 mL) after 5 min. These plasma and liver samples were applied on OASIS HLB  Extraction Cartridge (Nihon Waters, Tokyo) and washed with distilled water (3 mL) and 10z methanol (2 mL). UFX and I.S. were eluted with acetonitrile (2 mL) and dried under a nitrogen gas stream at 409 C. The residue was further dissolved in solvent (0.1 mL, 50 mM NaOH: methanol＝1:2) to prepare an HPLC sample. Prepared HPLC samples (20 mL) were injected into the TSK-gel ODS-120T  5 mm (4.6 mm I.D.×250 mm, TOSOH, Tokyo, Japan)ˆtted with TSK guardgel ODS-120T (3.2 mm I.D.×15 mm, TOSOH, Tokyo, Japan). The mobile phase was composed of 50 mM phosphate buŠer (pH 4.0)-acetonitrile. The ‰ow rate and column temperature were 1.0 mL/min and 409 C, respectively. UFX and I.S. were detected by UV (275 nm). The quantitation limit was 0.1 mg/mL. Hepatic uptake study in vivo: Under ether anesthesia, UFX (1, 5 and 25 mg/kg) was administered to rats via the caudal vein. CysA (30 mg/kg) was administered 5 min before UFX (1 mg/kg) administration. Blood samples were collected from the femoral artery cannulated with polyethylene tubes at designed time points at 1, 2 and 5 min after administration. After 1, 2 or 5 min, the rats were killed and liver tissues were excised. When we assume that the hepatic uptake of UFX was measured in a short period of time, during which eOEux, excretion and metabolism were negligible, the hepatic uptake should be proportional to AUC0-t. By dividing Ch, t and AUC0-t by Cp, t, CLh, uptake was obtained from the initial slope of the plot of C h, t /C p, t vs. AUC 0-t /C p, t . 11, 14) AUC0-t, Ch, t, Cp, t and CLh, uptake represent the area under the plasma concentration-time curve from 0 to t, the hepatic concentration at time t, the plasma concentration at time t and the hepatic uptake clearance, respectively.
Hepatocyte uptake study in vitro: The Uptake of [ 14 C]-UFX was initiated by adding the ligand solution (25 mL) to the cell suspension (1.25×10 6 cells/mL, 100 mL) preincubated at 379 C for 1 min. At the designed time point, the cells were separated from the medium using a centrifugalˆltration method so that the reaction was terminated. 15, 16) The radioactivity in the medium and cells was determined using a liquid scintillation counter. The uptake value (mL/mg protein) was determined by dividing the amount in cells by the concentration in the medium. We assumed that the eOEux of the substrate across the bile canalicular membrane would be negligible because the uptake of UFX was measured in a short period of time to estimate the initial uptake process.
Data analysis: The intrinsic hepatic uptake clearance (CLint, uptake) in vivo was calculated using the following equation according to a well-stirred model:
CLint, uptake ＝CL h, uptake ･R B ･Q h/( fp･(Qh-CLh, uptake)) (1) where RB is the blood-to-plasma concentration ratio (RB ＝1.0; measured in our laboratory), fp is the plasma unbound fraction ( fp＝0.50; measured in our laboratory) and Qh is the liver blood ‰ow rate (Qh＝41.5 mL/min/kg). 17) The kinetic parameters for UFX uptake in vitro were calculated according to the following equation:
V0＝Vmax1･S/(Km1＋S)＋Vmax2･S/(Km2＋S)＋Pdif･S (3) where V0, Vmax, S, Km and Pdif represent the initial uptake rate (pmol/min/mg protein), the maximum uptake rate (pmol/min/mg protein), the drug concentration in the medium ( mM), Michaelis-Menten constant ( mM) and the nonspeciˆc uptake clearance ( mL/min/mg protein), respectively. Theˆtting was performed by an iterative nonlinear least-squares method using a MULTI program.
18) The Damping Gauss Newton method was used forˆtting algorithm.
Statistics: Date were presented as mean±S.E. Statistical analysis was performed using Dunnett's multiple comparison following two-way ANOVA by SAS (SAS Institute Japan). pº0.05 and pº0.01 were regarded as signiˆcant.
Results
Hepatic uptake of UFX in vivo: The hepatic uptake clearances of UFX in vivo were evaluated by integration plot analysis (Fig. 2) . Each plot was a straight line, with the slope corresponding to the early-phase uptake clearance CLh, uptake. The CLh, uptake of UFX at a dose of 1 mg/kg was estimated to be 37.7 mL/min/kg ( Table 1) . This CLh, uptake was decreased by co-administration of CysA. The CL h, uptake at doses of 5 mg/kg and 25 mg/kg were 19.8 and 22.4 mL/min/kg respectively, which were smaller than that at a dose of 1 mg/kg ( Table 1) . As well, the CLint, uptake of UFX at a dose of 1 mg/kg was calculated to be 807 mL/min/kg, which was higher than those at doses of 5 mg/kg and 25 mg/kg and in the presence of CysA ( Table 1) .
Concentration dependence of [ 14 C]-UFX uptake by isolated rat hepatocytes: The uptake of UFX for 1 min declined as the concentration increased, indicating that the uptake possessed a saturable component (Fig. 3) . The kinetic parameters were obtained based on equation (Fig. 4) . On the other hand, [ 14 C]-UFX was not markedly taken up by hepatocytes at 49 C, revealing that the uptake of [ 14 C]-UFX was dependent on temperature (Fig. 4) . This uptake of [ 14 C]-UFX at 379 C was reduced in the presence of 30 mM CysA (Fig. 4) .
EŠects of various transporter inhibitors on [ 14 C]-UFX uptake by isolated rat hepatocytes: To determine the involvement of known transporters in hepatic uptake of UFX, the eŠects of Oatp1a1 inhibitors (TC, BSP, E1-3S, E2-17G, ICG, ouabain and CysA), Oatp1a4 inhibitors (TC, digoxin, BSP, E1-3S, E2-17G, ouabain and CysA), OAT2 substrate (PAH), OAT2 inhibitor (ICG), OCT1 inhibitor (cimetidine), Ntcp substrate (TC) and Ntcp inhibitors (BSP, E1-3S and CysA) on [ 14 C]-UFX (0.3 mM) uptake were examined for 1 min ( Table 2) . TC (1000 mM), E1-3S (1000 mM) and CysA (0.3-30 mM) sig- Table 2) . EŠects of several quinolone antibiotics on [
14 C]-UFX uptake by isolated rat hepatocytes: The eŠects of several quinolone antibiotics on [
14 C]-UFX (0.3 mM) uptake were examined for 1 min ( Table 3) . Unlabeled UFX inhibited the uptake of [
14 C]-UFX in a concentration-dependent manner. The other quinolone antibiotics, except for LFLX (0.5 and 5 mM), LVFX (0.5 mM) and SPFX (0.5 mM), reduced the uptake of [ 14 C]-UFX ( Table 3) .
Discussion
In this study, we comprehensively examined the mechanism of hepatic uptake of UFX, an active metabolite of a new quinolone antibiotic PUFX, in vivo and in vitro. Our results revealed that UFX was taken up by rat hepatocytes via a carrier-mediated transport system. This transport system was common to quinolone antibiotics.
The hepatic uptake of UFX in vivo, was evaluated by integration plot analysis (Fig. 2) . The CLh, uptake of UFX at a dose of 1 mg/kg was calculated to be 37.7 mL/min/kg ( Table 1) . This value was close to that of hepatic blood ‰ow in rats under ether anesthesia (41.5 mL/min/kg). 17) In addition, the CLint, uptake of UFX at a dose of 1 mg/kg was calculated to be 807 mL/min/kg ( Table 1) , being much higher than the blood ‰ow rate. These reveal that UFX uptake is very fast and blood ‰ow limited.
The CLh, uptake of 1 mg/kg UFX was higher than those at higher doses: The CLh, uptake at doses of 5 mg/kg and 25 mg/kg were 52.6z and 59.5z of that at 1 mg/kg, respectively ( Table 1) . This indicates that the hepatic uptake of UFX at doses of 5 mg/kg and 25 mg/kg are saturated. In addition, the CLh, uptake of UFX was decreased by pretreatment with CysA ( Table 1) . These results in vivo suggest that saturable system, which is sensitive to CysA, is involved in the hepatic uptake of UFX. It has been reported that CysA is an inhibitor of not only ATP binding cassette transporters localized on canalicular membranes, 19) e.g. P-glycoprotein and multispeciˆc organic anion transporter (MRP2), but also the uptake transporters on the sinusoidal membranes, e.g. Oatp1a1, Oatp1a4 and Ntcp. 20, 21) Because CysA reduced the CLh, uptake, it is considered that the uptake system on basolateral membrane which is common to CysA is involved in the hepatic uptake of UFX.
The kinetic analysis in vitro showed that UFX uptake consisted of a saturable component and a nonsaturable component (Fig. 3) . By comparing Vmax/Km with Pdif, the contribution of saturable and nonsaturable components to the UFX uptake was calculated to be 43z and 57z of total uptake, respectively, at linear conditions. Since the Km value (4.9 mM) is higher than clinical plasma concentration, saturable component would not be saturated under clinical usage. In an in vivo study (Fig.  2) , the plasma concentrations of unbound UFX at 5 mg/kg and 25 mg/kg administration at 1 min were approximately 23 mM and 143 mM, respectively. Because these values are much higher than the Km value, it is ascertained that the hepatic uptakes of UFX at 5 mg/kg and 25 mg/kg are saturated. The contribution of the nonsaturable component (approx. 57z of total uptake) was close to the value of uptake at 49 C (approx. 58z of control: Table 2 ), implying that this process would be nonspeciˆc passive diŠusion.
The time course of uptake of [ 14 C]-UFX (0.3 mM) by hepatocytes was determined in vitro (Fig. 4) . The uptake of [ 14 C]-UFX at 379 C was linear up to 1 min and reached equilibrium after 2 to 5 min, but uptake of [ 14 C]-UFX was reduced at 49 C (Fig. 4) . In addition, the uptake of [ 14 C]-UFX at 379 C was reduced in the presence of 30 mM CysA (Fig. 4) . CysA concentrationdependently and signiˆcantly inhibited the uptake of [ 14 C]-UFX ( Table 2) . These results in an in vitro study were compatible with those in an in vivo study in which CysA inhibited the CLh, uptake of UFX. Therefore, it is revealed that the uptake of [ 14 C]-UFX is dependent on temperature and competitively inhibited by CysA.
Some studies have investigated the mechanism of hepatic uptake of quinolone antibiotics. [9] [10] [11] However, it has not been clariˆed what kind of transporters mediate the hepatic uptake of quinolone antibiotics. Shitara et al. reported that CysA inhibited the rat Oatp1a1 and Oatp1a4-mediated transport 21) and inhibited the transporter-mediated uptake of cerivastatin, a substrate of OATP2, in the human hepatocyte. 22) Schroeder et al. reported that CysA inhibited Ntcp-mediated substrates transport.
al. discussed that several quinolone antibiotics are taken up by liver cells via a common transporter and that the lipophilicity may contribute to the a‹nity for the transporter.
11) Sasabe et al. suggested that hepatic uptake of GPFX is via carrier-mediated active transport 9) and there is a diŠerence in transport activity in the hepatic uptake process between GPFX and LFLX.
10) The present study has suggested that quinolone antibiotics, including UFX, are taken up by hepatocytes via carriermediated active transporters. As there was a little diŠer-ence in degree of inhibitory eŠects on the uptake of [
14 C]-UFX among quinolone antibiotics, there might be a diŠerence in the a‹nity for the transporters. There are some reports examining the involvement of active transporters in the distribution of quinolone antibiotics to various organs. It is reported that HSR-903 26) and GPFX 27) are taken up by the lung via carrier-mediated transport mechanism. Ito et al. suggest that the basolateral transport of LVFX and GPFX is mediated by speciˆc transport system for quinolone and distinct from the organic cation or organic anion transport systems in the kidney. 28) Moreover, Gri‹ths et al. report that the uptake of cipro‰oxacin from the basolateral side of the intestinal epithelial cell line is mediated by an active transporter. 29) From these cumulative data, it is indicated that quinolone antibiotics have a‹nity to some active transport systems in various organs. These transport systems have not been identiˆed yet. We infer that there are quinolone antibioticsspeciˆc active transport systems in various organs, including the liver.
In a previous study, 3) we reported that the biliary clearance (CLbile) and the volume of distribution at the steady-state (Vss) of UFX were decreased by pretreatment with CysA. Since CysA decreased the CLh, uptake of UFX in this study, a decrease of the CL bile by pretreatment with CysA was due to not only the inhibition of excretion into the bile, but also the inhibition of uptake by the liver. This reveals that the hepatic uptake is an important factor to determine the degree of excretion into the bile. As multiple transport systems, including P-glycoprotein, are also involved in the biliary excretion of UFX across canalicular membranes, 3) it is demonstrated that UFX is taken up by the liver and excreted into bile eŠectively via active transport systems. Yamazaki et al. reported that the CLbile and Vss of GPFX were decreased by pretreatment of CysA 30) as in the case of UFX. The similar mechanism of excretion into the bile may exist among some quinolone antibiotics.
In conclusion, UFX was taken up by rat hepatocytes via a carrier-mediated transport system. This transport system was not identical with known transporters, but common to quinolone antibiotics.
